Evidence map›Paper›PMID 36754712›Full record

SynthesisSeminars in oncology2022

Predictors of treatment refusal in patients with colorectal cancer: A systematic review.

Yoshan Moodley, Kumeren Govender, Jacqueline van Wyk, Seren Reddy, Yuming Ning, Steven Wexner, Laura Stopforth, Shona Bhadree, Vasudevan Naidoo, Shakeel Kader and 3 more

Open access · greenAbstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Seminars in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.7field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 3 countries.

Yoshan MoodleyGastrointestinal Cancer Research Group, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa; Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa. Electronic address: moodleyyo@ukzn.ac.za.
Kumeren GovenderNuffield Department of Medicine, John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom.
Jacqueline van WykSchool of Clinical Medicine, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa; Department of Health Sciences Education, University of Cape Town, Cape Town, South Africa.
Seren ReddyDepartment of Electronic and Computer Engineering, Durban University of Technology, Durban, South Africa.
Yuming NingDepartment of Surgery, Columbia University, New York, NY, USA.
Steven WexnerEllen Leifer Shulman and Steven Shulman Digestive Disease Center, Cleveland Clinic Florida, Weston, FL, USA.
Laura StopforthGastrointestinal Cancer Research Group, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.
Shona BhadreeGastrointestinal Cancer Research Group, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.
Vasudevan NaidooGastrointestinal Cancer Research Group, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.
Shakeel KaderGastrointestinal Cancer Research Group, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.
Shalen CheddieGastrointestinal Cancer Research Group, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.
Alfred I NeugutDepartment of Medicine and Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA.
Ravi P KiranDepartment of Surgery, Columbia University, New York, NY, USA.
University of KwaZulu-Natal · ZAColumbia University · USCleveland Clinic Florida · USColumbia University Irving Medical Center · USDurban University of Technology · ZAJohn Radcliffe Hospital · GBStellenbosch University · ZAUniversity of Cape Town · ZA

Funding

Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Anil K Rustgi · 1985 to 2026
$115.3M
A clinical prediction rule for identifying South African colorectal cancer patients who will fail to engage in oncology careK43CA268978 · NCI · UNIVERSITY OF KWAZULU-NATAL · PI MOODLEY, YOSHAN · 2021 to 2025
$282k
NCI NIH HHS K43 CA268978NCI NIH HHS P30 CA013696
6 · The paper itself

Abstract

This systematic review was conducted to investigate predictors of treatment refusal in colorectal cancer (CRC) patients. An understanding of these predictors would inform statistical models for the identification of high-risk patients who might benefit from interventions that seek to improve treatment compliance. We performed a search of PubMed and Scopus to identify potentially relevant studies on predictors of treatment refusal in CRC patients that were published between January 1, 2000 and December 31, 2021. We screened manuscripts using predefined eligibility criteria. Information on study design, study location, patient characteristics, treatments, rates and predictors of treatment refusal, and the impact of treatment refusal on mortality or survival were collected from eligible studies. Study quality was assessed using the Newcastle-Ottawa score. The overall findings of the review process were summarized using descriptive statistics and a narrative synthesis. A total of 13 studies were included in this review. Ten studies reported on refusal of CRC surgery, refusal rate: 0.25%-3.26%; three studies reported on chemotherapy refusal (one of which reported on both surgery and chemotherapy refusal), refusal rate: 7.8%-41.5%; and one study reported on refusal of any cancer treatment, refusal rate: 8.7%. The bulk of the published literature confirmed the harmful association between treatment refusal and poor survival outcomes in CRC patients. Frequently cited predictors of treatment refusal included patient demographic characteristics (age, race, gender), clinical characteristics (disease stage, comorbidity), and factors that impact access to cancer care services (healthcare insurance, facility level). Potentially high rates of treatment refusal pose a challenge to CRC control. This review has identified several factors which must be considered when attempting to reduce treatment refusal in CRC patients. Furthermore, these factors should be tested as components of predictive risk models for this important outcome.

Indexed as

Colorectal NeoplasmsHumansTreatment RefusalColon cancerColorectal neoplasmsPredictorsRectal cancerTreatment refusal

Identifiers

PMID36754712
PMCPMC10023422
OpenAlexW4318426232

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.